Instead, the current standard of care for patients with EGFR ex20in NSCLC is conventional cytotoxic chemotherapy, which involves a higher level of toxicity compared to other treatments such as EGFR‐TKIs.12 This evidence concerns the gene EGFR and non-small cell lung carcinoma.